Hormonoresistance in advanced breast cancer: a new revolution in endocrine therapy. (May 2017)

• Record Type: Journal Article
• Authors: Augereau, Paule; Patsouris, Anne; Bourbouloux, Emmanuelle; Gourmelon, Carole; Abadie Lacourtoisie, Sophie; Berton Rigaud, Dominique; Soulié, Patrick; Frenel, Jean Sebastien; Campone, Mario
• Is Part Of: Therapeutic advances in medical oncology. Volume 9:Number 5(2017:Sep.)
• Page Start: 335
• Page End: 346
• Publication Date: 2017-05
• Subjects: adaptive mechanism -- CDK4/6 inhibitor -- hormonoresistance -- PI3K/mTOR inhibitor; Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.994005
• DOI: 10.1177/1758834017693195
• Languages: English
• ISSNs: 1758-8340

Abstract

Endocrine therapy is the mainstay of treatment of estrogen-receptor-positive (ER+) breast cancer with an overall survival benefit. However, some adaptive mechanisms in the tumor emerge leading to the development of a resistance to this therapy. A better characterization of this process is needed to overcome this resistance and to develop new tailored therapies. Mechanisms of resistance to hormone therapy result in activation of transduction signal pathways, including the cell cycle regulation with cyclin D/CDK4/6/Rb pathway. The strategy of combined hormone therapy with targeted agents has shown an improvement of progression-free survival (PFS) in several phase II or III trials, including three different classes of drugs: mTOR inhibitors, PI3K and CDK4/6 inhibitors. A recent phase III trial has shown that fulvestrant combined with a CDK 4/6 inhibitor doubles PFS in aromatase inhibitor-pretreated postmenopausal ER+ breast cancer. Other combinations are ongoing to disrupt the interaction between PI3K/AKT/mTOR and cyclin D/CDK4/6/Rb pathways. Despite these successful strategies, reliable and reproducible biomarkers are needed. Tumor genomics are dynamic over time, and blood-based biomarkers such as circulating tumor DNA represent a major hope to elucidate the adaptive mechanisms of endocrine resistance. The optimal combinations and biomarkers to guide this strategy need to be determined.